Physician profile
Robert Caifano
NPI 1568417533
$16,588.04
in general payments reported to CMS, 2019-2025
53 companies · $3,096 in 2025
The $3,096 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,683 · 2020: $751 · 2021: $2,132 · 2022: $2,547 · 2023: $2,380 · 2024: $3,001 · 2025: $3,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,451 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,451.22 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,852.87 | 2021-2025 | Vraylar, Ubrelvy, Creon |
| Novo Nordisk INC | $1,501.85 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,462.34 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,354.77 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $1,269.39 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $1,095.78 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $932.50 | 2019-2025 | Mounjaro, Emgality, Jardiance |
| Astellas Pharma US INC | $708.07 | 2019-2024 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $556.87 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Novartis Pharmaceuticals Corporation | $477.41 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $474.37 | 2019-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $431.94 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $301.00 | 2020-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $285.51 | 2019-2025 | Verquvo, Gardasil 9, Capvaxive |
| Biohaven Pharmaceutical Holding Company LTD. | $275.61 | 2022 |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $261.61 | 2021 | |
| Janssen Pharmaceuticals, INC | $256.31 | 2019-2024 | Xarelto |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $248.64 | 2023-2025 | Caplyta |
| Abbott Laboratories | $235.80 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amarin Pharma, INC. | $224.41 | 2019-2022 | |
| Baxter Healthcare | $207.90 | 2022 | |
| Allergan, INC. | $196.03 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $187.71 | 2019-2025 | Trintellix |
| Currax Pharmaceuticals LLC | $178.26 | 2022-2025 | Contrave, Nexletol, Nexlizet |
| Idorsia Pharmaceuticals US INC | $169.95 | 2022-2023 | Quviviq |
| Exact Sciences Corporation | $168.48 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Teva Pharmaceuticals USA, INC. | $128.33 | 2020-2023 | Ajovy |
| Ironwood Pharmaceuticals, INC | $127.13 | 2023-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $116.21 | 2024-2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $97.70 | 2023-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $92.80 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $62.88 | 2019-2021 | |
| Insulet Corporation | $61.93 | 2022-2023 | Omnipod |
| Axsome Therapeutics, INC. | $61.23 | 2024-2025 | Auvelity |
| Esperion Therapeutics, INC. | $59.77 | 2020-2021 | |
| Dexcom, INC. | $43.55 | 2024 | Dexcom G6 Transmitter |
| Verona Pharma, INC. | $42.19 | 2025 | Ohtuvayre |
| Bardy Diagnostics, INC. | $41.70 | 2022 | |
| Inspire Medical Systems, INC. | $39.59 | 2024-2025 | Inspire |
| Biogen, INC. | $37.42 | 2021-2022 | |
| Alkermes, INC. | $35.32 | 2022 | |
| Clarus Therapeutics INC. | $23.26 | 2021 | |
| Lundbeck LLC | $22.68 | 2025 | Rexulti |
| Alvogen INC | $22.22 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $21.64 | 2019 | |
| Boston Scientific Corporation | $20.24 | 2025 | Watchman Flx |
| Sunovion Pharmaceuticals INC. | $18.75 | 2021 | |
| Sumitomo Pharma America, INC. | $18.25 | 2025 | Gemtesa |
| Mannkind Corporation | $17.44 | 2019 | |
| Alfasigma USA, INC. | $16.94 | 2021 | |
| Vanda Pharmaceuticals INC. | $16.04 | 2022 | |
| Adlon Therapeutics L.P. | $13.91 | 2021 | |
| Tolmar, INC. | $13.54 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Caifano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.